| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC1763 |
| Trial ID | NCT03240861 |
| Disease | Malignant Neoplasm |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| Co-treatment | Filgrastim|Plerixafor |
| HLA | HLA-A*02:01 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
| Year | 2017 |
| Country | United States |
| Company sponsor | Jonsson Comprehensive Cancer Center |
| Other ID(s) | 15-000511|NCI-2017-00896|Ribas NYESO SCT Cancer |
| Cohort 1 | |||||||||
|
|||||||||